{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:21:49Z","timestamp":1792725709225,"version":"4.5.0"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Eye Research"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.exer.2025.110456","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T02:35:35Z","timestamp":1748313335000},"page":"110456","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Breaking barriers in ocular drug delivery for Uveitis: Advanced drug delivery systems, challenges and future prospects"],"prefix":"10.1016","volume":"257","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6481-6314","authenticated-orcid":false,"given":"Anju","family":"Ambekar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8701-7793","authenticated-orcid":false,"given":"Jagannath","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2198-7567","authenticated-orcid":false,"given":"Kavita","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.exer.2025.110456_bib1","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2174\/156720112801323125","article-title":"Controlled and continuous release ocular drug delivery systems: pros and cons","volume":"9","author":"Abdelkader","year":"2012","journal-title":"Curr. Drug Deliv."},{"issue":"7","key":"10.1016\/j.exer.2025.110456_bib2","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.3390\/biomedicines11071901","article-title":"The evolution of triamcinolone acetonide therapeutic use in retinal diseases: from off-label intravitreal injection to advanced nano-drug delivery systems","volume":"11","author":"Aceves-Franco","year":"2023","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.exer.2025.110456_bib3","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3390\/gels8020082","article-title":"Drug delivery challenges and current progress in nanocarrier-based ocular therapeutic system","volume":"8","author":"Akhter","year":"2022","journal-title":"Gels"},{"issue":"7","key":"10.1016\/j.exer.2025.110456_bib4","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1080\/17425247.2023.2219053","article-title":"Sustained release ocular drug delivery systems for glaucoma therapy","volume":"20","author":"Al-Qaysi","year":"2023","journal-title":"Expet Opin. Drug Deliv."},{"issue":"9","key":"10.1016\/j.exer.2025.110456_bib5","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.3390\/pharmaceutics15092273","article-title":"Topical sustained-release dexamethasone-loaded chitosan nanoparticles: assessment of drug delivery efficiency in a rabbit model of endotoxin-induced uveitis","volume":"15","author":"Alkholief","year":"2023","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.exer.2025.110456_bib6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4103\/meajo.meajo_78_21","article-title":"Single low-dose suprachoroidal triamcinolone acetonide injection in macular edema secondary to noninfectious posterior uveitis","volume":"30","author":"Anand","year":"2023","journal-title":"Middle East Afr. J. Ophthalmol."},{"issue":"9","key":"10.1016\/j.exer.2025.110456_bib7","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3390\/gels10090589","article-title":"Exploring hydrogel nanoparticle systems for enhanced ocular drug delivery","volume":"10","author":"Arabpour","year":"2024","journal-title":"Gels"},{"key":"10.1016\/j.exer.2025.110456_bib8","article-title":"Prednisolone loaded-cationic nanoemulsion formulation for uveitis management","volume":"92","author":"Attia","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"2","key":"10.1016\/j.exer.2025.110456_bib10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3390\/pharmaceutics13020228","article-title":"Dexamethasone plga microspheres for sub-tenon administration: influence of sterilization and tolerance studies","volume":"13","author":"Barbosa-Alfaro","year":"2021","journal-title":"Pharmaceutics"},{"issue":"12","key":"10.1016\/j.exer.2025.110456_bib11","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1080\/17425247.2016.1201059","article-title":"Application of lipid nanoparticles to ocular drug delivery","volume":"13","author":"Battaglia","year":"2016","journal-title":"Expet Opin. Drug Deliv."},{"issue":"2","key":"10.1016\/j.exer.2025.110456_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1473","article-title":"Nanocarrier mediated retinal drug delivery: overcoming ocular barriers to treat posterior eye diseases","volume":"10","author":"Bisht","year":"2018","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.exer.2025.110456_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12348-020-00225-z","article-title":"Preventing relapse in non-infectious uveitis affecting the posterior segment of the eye\u2013evaluating the 0.2 \u03bcg\/day fluocinolone acetonide intravitreal implant (ILUVIEN\u00ae)","volume":"10","author":"Bodaghi","year":"2020","journal-title":"J. Ophthalmic Inflamm. Infect."},{"key":"10.1016\/j.exer.2025.110456_bib14","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/978-1-4614-4711-5_3","article-title":"The blood-retina barrier: tight junctions and barrier modulation","author":"Campbell","year":"2013","journal-title":"Biol. Regul. blood-tissue barriers"},{"key":"10.1016\/j.exer.2025.110456_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2020.117216","article-title":"Hydrogel eye drops as a non-invasive drug carrier for topical enhanced adalimumab permeation and highly efficient uveitis treatment","volume":"253","author":"Chen","year":"2021","journal-title":"Carbohydr. Polym."},{"issue":"2","key":"10.1016\/j.exer.2025.110456_bib16","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2174\/1877912311202020082","article-title":"Novel nanomicellar formulation approaches for anterior and posterior segment ocular drug delivery","volume":"2","author":"Cholkar","year":"2012","journal-title":"Recent Pat. Nanomed."},{"key":"10.1016\/j.exer.2025.110456_bib17","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1208\/s12249-014-0244-2","article-title":"Nanomicellar topical aqueous drop formulation of rapamycin for back-of-the-eye delivery","volume":"16","author":"Cholkar","year":"2015","journal-title":"AAPS PharmSciTech"},{"issue":"3","key":"10.1016\/j.exer.2025.110456_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1167\/tvst.4.3.1","article-title":"Topical, aqueous, clear cyclosporine formulation design for anterior and posterior ocular delivery","volume":"4","author":"Cholkar","year":"2015","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.exer.2025.110456_bib19","article-title":"Microinjection via the suprachoroidal space: a review of a novel mode of administration","volume":"28","author":"Ciulla","year":"2022","journal-title":"Am. J. Manag. Care"},{"issue":"1","key":"10.1016\/j.exer.2025.110456_bib20","article-title":"Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate","volume":"2012","author":"Comstock","year":"2012","journal-title":"Int. J. Inflamm."},{"issue":"8","key":"10.1016\/j.exer.2025.110456_bib21","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.3390\/pharmaceutics13081224","article-title":"A review of ocular drug delivery platforms and drugs for infectious and noninfectious uveitis: the past, present, and future","volume":"13","author":"Conrady","year":"2021","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.exer.2025.110456_bib22","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3129\/i10-081","article-title":"Practical approach to the use of corticosteroids in patients with uveitis","volume":"45","author":"Cunningham","year":"2010","journal-title":"Can. J. Ophthalmol."},{"key":"10.1016\/j.exer.2025.110456_bib23","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1590\/S1984-82502010000300024","article-title":"Implants as drug delivery devices for the treatment of eye diseases","volume":"46","author":"da Silva","year":"2010","journal-title":"Brazilian J. Pharm. Sci."},{"issue":"17","key":"10.1016\/j.exer.2025.110456_bib24","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1039\/D0BM00532K","article-title":"The gamut of perspectives, challenges, and recent trends for in situ hydrogels: a smart ophthalmic drug delivery vehicle","volume":"8","author":"Das","year":"2020","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.exer.2025.110456_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124192","article-title":"Fostering the unleashing potential of nanocarriers-mediated delivery of ocular therapeutics","author":"Datta","year":"2024","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.exer.2025.110456_bib26","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3390\/pharmaceutics17020215","article-title":"Hydrogels and nanogels: pioneering the future of advanced drug delivery systems","volume":"17","author":"Delgado-Pujol","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.exer.2025.110456_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12249-019-1371-6","article-title":"Development, optimization, and in vitro\/in vivo characterization of enhanced lipid nanoparticles for ocular delivery of ofloxacin: the influence of pegylation and chitosan coating","volume":"20","author":"Eid","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.exer.2025.110456_bib28","first-page":"1","article-title":"Evaluation of ocular In-Situ hydro-Gel formulated prednisolone for controlling experimentally induced uveitis in rabbits","author":"Elshazly","year":"2024","journal-title":"Egypt. J. Vet. Sci."},{"issue":"9","key":"10.1016\/j.exer.2025.110456_bib29","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2174\/1381612822666151216145900","article-title":"Ocular drug delivery-new strategies for targeting anterior and posterior segments of the eye","volume":"22","author":"F Fangueiro","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.exer.2025.110456_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121938","article-title":"Customized cationic nanoemulsions loading triamcinolone acetonide for corneal neovascularization secondary to inflammatory processes","volume":"623","author":"Fernandes","year":"2022","journal-title":"Int. J. Pharm."},{"issue":"6","key":"10.1016\/j.exer.2025.110456_bib32","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.3390\/pharmaceutics15061622","article-title":"Transscleral delivery of dexamethasone-loaded microparticles using a dissolving microneedle array","volume":"15","author":"Fitaihi","year":"2023","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/j.exer.2025.110456_bib33","doi-asserted-by":"crossref","first-page":"9305","DOI":"10.3390\/molecules18089305","article-title":"An azabisphosphonate-capped poly (phosphorhydrazone) dendrimer for the treatment of endotoxin-induced uveitis","volume":"18","author":"Fruchon","year":"2013","journal-title":"Molecules"},{"issue":"5","key":"10.1016\/j.exer.2025.110456_bib34","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.mehy.2013.08.007","article-title":"Topical tacrolimus nanoemulsion, a promising therapeutic approach for uveitis","volume":"81","author":"Garg","year":"2013","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.exer.2025.110456_bib35","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/00002018-200225040-00002","article-title":"Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: a safety review","volume":"25","author":"Gaynes","year":"2002","journal-title":"Drug Saf."},{"key":"10.1016\/j.exer.2025.110456_bib36","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jconrel.2022.07.019","article-title":"Cyclosporine-loaded micelles for ocular delivery: investigating the penetration mechanisms","volume":"349","author":"Ghezzi","year":"2022","journal-title":"J. Contr. Release"},{"issue":"15","key":"10.1016\/j.exer.2025.110456_bib37","first-page":"5059","article-title":"Treatment of acute posterior uveitis by injection of triamcinolone acetonide into the suprachoroidal space using microneedles","volume":"54","author":"Gilger","year":"2013","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"3","key":"10.1016\/j.exer.2025.110456_bib38","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cvsm.2003.12.003","article-title":"Nonsteroidal anti-inflammatory drugs in veterinary ophthalmology","volume":"34","author":"Giuliano","year":"2004","journal-title":"Vet. Clin. Small Anim. Pract."},{"key":"10.1016\/j.exer.2025.110456_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.115082","article-title":"Microneedles for advanced ocular drug delivery","volume":"201","author":"Glover","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"46","key":"10.1016\/j.exer.2025.110456_bib40","doi-asserted-by":"crossref","first-page":"27835","DOI":"10.1039\/D0RA04971A","article-title":"Nanocarriers for ocular drug delivery: current status and translational opportunity","volume":"10","author":"Gorantla","year":"2020","journal-title":"RSC Adv."},{"issue":"3","key":"10.1016\/j.exer.2025.110456_bib41","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1124\/jpet.119.256933","article-title":"Ocular drug delivery: present innovations and future challenges","volume":"370","author":"Gote","year":"2019","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"16","key":"10.1016\/j.exer.2025.110456_bib42","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6528\/aafe36","article-title":"Evaluation of controlled-release triamcinolone acetonide-loaded mPEG-PLGA nanoparticles in treating experimental autoimmune uveitis","volume":"30","author":"Guo","year":"2019","journal-title":"Nanotechnology"},{"issue":"8","key":"10.1016\/j.exer.2025.110456_bib43","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/10717540701606426","article-title":"Sustained ocular drug delivery from a temperature and pH triggered novel in situ gel system","volume":"14","author":"Gupta","year":"2007","journal-title":"Drug Deliv."},{"issue":"1","key":"10.1016\/j.exer.2025.110456_bib44","article-title":"Microemulsion: new insights into the ocular drug delivery","volume":"2013","author":"Hegde","year":"2013","journal-title":"Int. Sch. Res. Not."},{"key":"10.1016\/j.exer.2025.110456_bib45","series-title":"Dermal and Ocular Toxicology: Fundamentals and Methods","author":"Hobson","year":"2020"},{"key":"10.1016\/j.exer.2025.110456_bib46","series-title":"Hydrogel-Forming Microneedles for Transdermal Drug Delivery","author":"Hou","year":"2023"},{"issue":"1","key":"10.1016\/j.exer.2025.110456_bib47","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2174\/1872211308666140130093301","article-title":"Drug delivery to the back of the eye following topical administration: an update on research and patenting activity","volume":"8","author":"Hs Boddu","year":"2014","journal-title":"Recent Pat. Drug Deliv. Formulation"},{"issue":"3","key":"10.1016\/j.exer.2025.110456_bib48","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/ICU.0b013e3281108000","article-title":"Drug delivery methods for posterior segment disease","volume":"18","author":"Hsu","year":"2007","journal-title":"Curr. Opin. Ophthalmol."},{"issue":"1\u20132","key":"10.1016\/j.exer.2025.110456_bib49","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijpharm.2018.09.015","article-title":"Directing the nanoparticle formation by the combination with small molecular assembly and polymeric assembly for topical suppression of ocular inflammation","volume":"551","author":"Huang","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.exer.2025.110456_bib50","doi-asserted-by":"crossref","DOI":"10.1177\/24741264241246314","article-title":"Suprachoroidal drug delivery for macular edema associated with noninfectious uveitis","author":"Huang","year":"2024","journal-title":"J. Vitreoretin. Dis."},{"issue":"14","key":"10.1016\/j.exer.2025.110456_bib51","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.addr.2005.09.004","article-title":"Topical and systemic drug delivery to the posterior segments","volume":"57","author":"Hughes","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.exer.2025.110456_bib52","first-page":"1613","article-title":"Dexamethasone intravitreal implant for the treatment of noninfectious uveitis","author":"Hunter","year":"2011","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.exer.2025.110456_bib53","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jconrel.2020.07.031","article-title":"Intravitreal hydrogels for sustained release of therapeutic proteins","volume":"326","author":"Ilochonwu","year":"2020","journal-title":"J. Contr. Release"},{"issue":"2","key":"10.1016\/j.exer.2025.110456_bib54","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2017.08.007","article-title":"Immunosuppression for the uveitides","volume":"125","author":"Jabs","year":"2018","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.exer.2025.110456_bib55","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.ophtha.2006.02.021","article-title":"Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four\u2013week results of a multicenter randomized clinical study","volume":"113","author":"Jaffe","year":"2006","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.exer.2025.110456_bib56","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1167\/iovs.07-0066","article-title":"Coated microneedles for drug delivery to the eye","volume":"48","author":"Jiang","year":"2007","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"4","key":"10.1016\/j.exer.2025.110456_bib57","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2478\/acph-2019-0054","article-title":"In vitro evaluation of stearylamine cationic nanoemulsions for improved ocular drug delivery","volume":"69","author":"Juri\u0161i\u0107 Dukovski","year":"2019","journal-title":"Acta Pharm."},{"key":"10.1016\/j.exer.2025.110456_bib58","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s13346-018-0504-x","article-title":"A stimulus-responsive, in situ-forming, nanoparticle-laden hydrogel for ocular drug delivery","volume":"8","author":"Kabiri","year":"2018","journal-title":"Drug Deliv. Transl. Res."},{"issue":"20","key":"10.1016\/j.exer.2025.110456_bib59","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.2217\/nnm-2023-0123","article-title":"Polymeric micelles loaded in situ gel with prednisolone acetate for ocular inflammation: development and evaluation","volume":"18","author":"Kaushal","year":"2023","journal-title":"Nanomedicine"},{"issue":"10","key":"10.1016\/j.exer.2025.110456_bib60","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/j.ophtha.2011.07.027","article-title":"Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial","volume":"118","author":"Kempen","year":"2011","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.exer.2025.110456_bib61","doi-asserted-by":"crossref","first-page":"55","DOI":"10.22270\/ajprd.v12i1.1349","article-title":"An updated comprehensive review on novel drug delivery systems (NDDS) in the pharmaceuticals","volume":"12","author":"Khadam","year":"2024","journal-title":"Asian J. Pharmaceut. Res. Dev."},{"issue":"6","key":"10.1016\/j.exer.2025.110456_bib62","doi-asserted-by":"crossref","first-page":"662","DOI":"10.3109\/10837450.2014.910807","article-title":"Development and evaluation of a novel in situ gel of sparfloxacin for sustained ocular drug delivery: in vitro and ex vivo characterization","volume":"20","author":"Khan","year":"2015","journal-title":"Pharmaceut. Dev. Technol."},{"issue":"7","key":"10.1016\/j.exer.2025.110456_bib63","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1167\/iovs.06-1305","article-title":"Downregulation of endotoxin-induced uveitis by intravitreal injection of vasoactive intestinal peptide encapsulated in liposomes","volume":"48","author":"Lajavardi","year":"2007","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"1","key":"10.1016\/j.exer.2025.110456_bib64","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jconrel.2009.05.033","article-title":"New formulation of vasoactive intestinal peptide using liposomes in hyaluronic acid gel for uveitis","volume":"139","author":"Lajavardi","year":"2009","journal-title":"J. Contr. Release"},{"issue":"12","key":"10.1016\/j.exer.2025.110456_bib65","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1016\/j.cclet.2021.03.037","article-title":"Bioinspired self-assembly supramolecular hydrogel for ocular drug delivery","volume":"32","author":"Li","year":"2021","journal-title":"Chin. Chem. Lett."},{"issue":"11","key":"10.1016\/j.exer.2025.110456_bib66","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3390\/ph13110351","article-title":"Nanotechnology for the treatment of allergic conjunctival diseases","volume":"13","author":"Liu","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.exer.2025.110456_bib67","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.2147\/IJN.S349360","article-title":"PD-1 targeted nanoparticles inhibit activated T cells and alleviate autoimmunity via suppression of cellular energy metabolism mediated by PKM2","author":"Liu","year":"2022","journal-title":"Int. J. Nanomed."},{"issue":"24","key":"10.1016\/j.exer.2025.110456_bib68","doi-asserted-by":"crossref","first-page":"25377","DOI":"10.1021\/acsnano.3c08869","article-title":"Multifunctional hydrogel eye drops for synergistic treatment of ocular inflammatory disease","volume":"17","author":"Liu","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.exer.2025.110456_bib69","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jconrel.2019.01.018","article-title":"Controlled release of corticosteroid with biodegradable nanoparticles for treating experimental autoimmune uveitis","volume":"296","author":"Luo","year":"2019","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.exer.2025.110456_bib70","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s10753-012-9546-2","article-title":"Anti-inflammatory effects of Z-ligustilide nanoemulsion","volume":"36","author":"Ma","year":"2013","journal-title":"Inflammation"},{"issue":"21","key":"10.1016\/j.exer.2025.110456_bib71","doi-asserted-by":"crossref","first-page":"27040","DOI":"10.1021\/acsami.4c01732","article-title":"Combination of PEGylation and cationization on phospholipid-coated cyclosporine nanosuspensions for enhanced ocular drug delivery","volume":"16","author":"Ma","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"4","key":"10.1016\/j.exer.2025.110456_bib73","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3390\/pharmaceutics13040444","article-title":"Development of triamcinolone acetonide-loaded microemulsion as a prospective ophthalmic delivery system for treatment of uveitis: in vitro and in vivo evaluation","volume":"13","author":"Mahran","year":"2021","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.exer.2025.110456_bib74","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/IAE.0000000000002901","article-title":"Uveitis treated with dexamethasone implant","volume":"41","author":"Mathis","year":"2021","journal-title":"Retina"},{"key":"10.1016\/j.exer.2025.110456_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105735","article-title":"A grafted copolymer-based nanomicelles for topical ocular delivery of everolimus: formulation, characterization, ex-vivo permeation, in-vitro ocular toxicity, and stability study","volume":"159","author":"Mehra","year":"2021","journal-title":"Eur. J. Pharmaceut. Sci."},{"issue":"8","key":"10.1016\/j.exer.2025.110456_bib76","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.drudis.2019.05.006","article-title":"Therapeutic implications of nanomedicine for ocular drug delivery","volume":"24","author":"Meng","year":"2019","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.exer.2025.110456_bib77","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8844030","article-title":"Dendrimers: a new race of pharmaceutical nanocarriers","volume":"2021","author":"Mittal","year":"2021","journal-title":"BioMed Res. Int."},{"issue":"7","key":"10.1016\/j.exer.2025.110456_bib78","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3390\/children11070769","article-title":"Uveitis in the pediatric population and therapeutic management: a current literature review","volume":"11","author":"Modrzejewska","year":"2024","journal-title":"Children"},{"issue":"19","key":"10.1016\/j.exer.2025.110456_bib79","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.3390\/molecules25194377","article-title":"Utilization of polymer-lipid hybrid nanoparticles for targeted anti-cancer therapy","volume":"25","author":"Mohanty","year":"2020","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.exer.2025.110456_bib80","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/s12668-020-00752-y","article-title":"Mucoadhesive micro-\/nano carriers in ophthalmic drug delivery: an overview","volume":"10","author":"Naik","year":"2020","journal-title":"BioNanoScience"},{"issue":"13","key":"10.1016\/j.exer.2025.110456_bib81","first-page":"5266","article-title":"Topical nanomicelles for the treatment of intermediate and posterior uveitis: focus on micelle size","volume":"55","author":"Natarajan","year":"2014","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2025.110456_bib83","series-title":"Development and Evaluation of a Nanomicellar Eye Drop Formulation of Dexamethasone for Posterior Uveitis","author":"Patel","year":"2014"},{"issue":"3","key":"10.1016\/j.exer.2025.110456_bib85","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/ICU.0000000000000850","article-title":"Complications of intravitreal injections: 2022","volume":"33","author":"Patel","year":"2022","journal-title":"Curr. Opin. Ophthalmol."},{"issue":"1","key":"10.1016\/j.exer.2025.110456_bib86","doi-asserted-by":"crossref","first-page":"71","DOI":"10.17219\/pim\/166413","article-title":"A review on topical ophthalmic drug delivery system: reference to viscosity enhancer","volume":"54","author":"Pawar","year":"2024","journal-title":"Polym. Med."},{"key":"10.1016\/j.exer.2025.110456_bib87","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2147\/OPTH.S276109","article-title":"Endothelin-1 serum concentration in pediatric chronic idiopathic uveitis","author":"Powierza","year":"2021","journal-title":"Clin. Ophthalmol."},{"issue":"4","key":"10.1016\/j.exer.2025.110456_bib88","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1021\/acs.biomac.6b00054","article-title":"Phenylboronic-acid-based polymeric micelles for mucoadhesive anterior segment ocular drug delivery","volume":"17","author":"Prosperi-Porta","year":"2016","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.exer.2025.110456_bib89","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.850757","article-title":"Recent developments of nanostructures for the ocular delivery of natural compounds","volume":"10","author":"Razavi","year":"2022","journal-title":"Front. Chem."},{"key":"10.1016\/j.exer.2025.110456_bib90","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jconrel.2021.03.035","article-title":"Topical tacrolimus nanocapsules eye drops for therapeutic effect enhancement in both anterior and posterior ocular inflammation models","volume":"333","author":"Rebibo","year":"2021","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.exer.2025.110456_bib91","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000431197","article-title":"Nonsteroidal anti-inflammatory drugs in the treatment of retinal diseases","volume":"55","author":"Rodrigues","year":"2016","journal-title":"Retin. Pharmacother."},{"issue":"8","key":"10.1016\/j.exer.2025.110456_bib92","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1167\/iovs.13-12296","article-title":"Improved anti-inflammatory effects in rabbit eye model using biodegradable poly beta-amino ester nanoparticles of triamcinolone acetonide","volume":"54","author":"Sabzevari","year":"2013","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"1","key":"10.1016\/j.exer.2025.110456_bib93","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejpb.2012.12.010","article-title":"Polymeric triamcinolone acetonide nanoparticles as a new alternative in the treatment of uveitis: in vitro and in vivo studies","volume":"84","author":"Sabzevari","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"4","key":"10.1016\/j.exer.2025.110456_bib94","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.exer.2005.09.003","article-title":"Treatment of experimental autoimmune uveoretinitis with poly (lactic acid) nanoparticles encapsulating betamethasone phosphate","volume":"82","author":"Sakai","year":"2006","journal-title":"Exp. Eye Res."},{"issue":"3","key":"10.1016\/j.exer.2025.110456_bib95","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1167\/iovs.10-5676","article-title":"Therapeutic effect of stealth-type polymeric nanoparticles with encapsulated betamethasone phosphate on experimental autoimmune uveoretinitis","volume":"52","author":"Sakai","year":"2011","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2025.110456_bib96","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejpb.2016.10.009","article-title":"Lipid nanoparticles (SLN, NLC): overcoming the anatomical and physiological barriers of the eye\u2013Part I\u2013Barriers and determining factors in ocular delivery","volume":"110","author":"S\u00e1nchez-L\u00f3pez","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.exer.2025.110456_bib97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40123-014-0027-6","article-title":"Use of the fluocinolone acetonide intravitreal implant for the treatment of noninfectious posterior uveitis: 3-year results of a randomized clinical trial in a predominantly Asian population","volume":"4","author":"Sangwan","year":"2015","journal-title":"Ophthalmol. Ther"},{"issue":"15","key":"10.1016\/j.exer.2025.110456_bib99","first-page":"1076","article-title":"Novel aqueous nanomicellar formulations containing fluocinolone acetonide for the treatment of posterior uveitis","volume":"54","author":"Shah","year":"2013","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"6","key":"10.1016\/j.exer.2025.110456_bib100","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1089\/jop.2021.0089","article-title":"Sustained release biodegradable microneedles of difluprednate for delivery to posterior eye","volume":"38","author":"Shelley","year":"2022","journal-title":"J. Ocul. Pharmacol. Therapeut."},{"key":"10.1016\/j.exer.2025.110456_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123205","article-title":"Dissolvable hybrid microneedle patch for efficient delivery of curcumin to reduce intraocular inflammation","volume":"643","author":"Shi","year":"2023","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.exer.2025.110456_bib102","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1089\/108076804773710830","article-title":"Scleral permeability of a small, single-stranded oligonucleotide","volume":"20","author":"Shuler","year":"2004","journal-title":"J. Ocul. Pharmacol. Therapeut."},{"issue":"11","key":"10.1016\/j.exer.2025.110456_bib103","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1136\/bjophthalmol-2018-312765","article-title":"Dexamethasone implant for non-infectious uveitis: is it cost-effective?","volume":"103","author":"Squires","year":"2019","journal-title":"Br. J. Ophthalmol."},{"issue":"3","key":"10.1016\/j.exer.2025.110456_bib104","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1152\/physrev.00021.2004","article-title":"The retinal pigment epithelium in visual function","volume":"85","author":"Strauss","year":"2005","journal-title":"Physiol. Rev."},{"issue":"1","key":"10.1016\/j.exer.2025.110456_bib105","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/10717544.2019.1622608","article-title":"New micelle myricetin formulation for ocular delivery: improved stability, solubility, and ocular anti-inflammatory treatment","volume":"26","author":"Sun","year":"2019","journal-title":"Drug Deliv."},{"key":"10.1016\/j.exer.2025.110456_bib106","doi-asserted-by":"crossref","DOI":"10.5772\/32238","article-title":"Ocular surface squamous neoplasia","volume":"30","author":"Tananuvat","year":"2012","journal-title":"Intraepithelial Neoplasia"},{"issue":"1","key":"10.1016\/j.exer.2025.110456_bib107","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12951-024-02402-x","article-title":"OCTN2-and ATB0,+-targeted nanoemulsions for improving ocular drug delivery","volume":"22","author":"Tang","year":"2024","journal-title":"J. Nanobiotechnol."},{"issue":"Suppl. 1","key":"10.1016\/j.exer.2025.110456_bib108","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000318021","article-title":"New developments in corticosteroid therapy for uveitis","volume":"224","author":"Taylor","year":"2010","journal-title":"Ophthalmologica"},{"issue":"3","key":"10.1016\/j.exer.2025.110456_bib109","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3390\/pharmaceutics12030253","article-title":"Assembling surfactants-mucoadhesive polymer nanomicelles (ASMP-nano) for ocular delivery of cyclosporine-A","volume":"12","author":"Terreni","year":"2020","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.exer.2025.110456_bib110","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/17425247.2016.1218460","article-title":"Minimally invasive microneedles for ocular drug delivery","volume":"14","author":"Thakur Singh","year":"2017","journal-title":"Expet Opin. Drug Deliv."},{"issue":"8","key":"10.1016\/j.exer.2025.110456_bib112","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.ophtha.2014.02.003","article-title":"Treatment with repeat dexamethasone implants results in long-term disease control in eyes with noninfectious uveitis","volume":"121","author":"Tomkins-Netzer","year":"2014","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.exer.2025.110456_bib113","article-title":"Cytotoxicity of dendrimers","volume":"9","author":"Trzepi\u0144ski","year":"2019","journal-title":"Biomolecules"},{"issue":"7","key":"10.1016\/j.exer.2025.110456_bib114","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1517\/14656566.2011.571209","article-title":"Dexamethasone for ocular inflammation","volume":"12","author":"V Saraiya","year":"2011","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.exer.2025.110456_bib115","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1208\/s12249-014-0100-4","article-title":"Novel dexamethasone-loaded nanomicelles for the intermediate and posterior segment uveitis","volume":"15","author":"Vaishya","year":"2014","journal-title":"AAPS PharmSciTech"},{"issue":"8","key":"10.1016\/j.exer.2025.110456_bib116","first-page":"765","article-title":"Uveitis therapy: the corticosteroid options","volume":"80","author":"Valdes","year":"2020","journal-title":"Drugs (Basel)"},{"key":"10.1016\/j.exer.2025.110456_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114721","article-title":"Nano-based eye drop: topical and noninvasive therapy for ocular diseases","volume":"194","author":"Wang","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.exer.2025.110456_bib118","first-page":"e30","article-title":"Dendrimer and dendrimer gel\u2010derived drug delivery systems: breaking bottlenecks of topical administration of glaucoma medications","volume":"2","author":"Wang","year":"2023","journal-title":"MedComm\u2013Biomaterials Appl"},{"key":"10.1016\/j.exer.2025.110456_bib119","first-page":"10","article-title":"Intravitreal 0.18-mg fluocinolone acetonide implant for pediatric uveitis","author":"Wangyu","year":"2022","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.exer.2025.110456_bib120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/nyas.12824","article-title":"Development of a dexamethasone intravitreal implant for the treatment of noninfectious posterior segment uveitis","volume":"1358","author":"Whitcup","year":"2015","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"9","key":"10.1016\/j.exer.2025.110456_bib121","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1002\/jbm.a.34976","article-title":"Hyaluronic acid\u2010based nanocomposite hydrogels for ocular drug delivery applications","volume":"102","author":"Widjaja","year":"2014","journal-title":"J. Biomed. Mater. Res., Part A"},{"key":"10.1016\/j.exer.2025.110456_bib122","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1007\/s13346-019-00703-5","article-title":"Facile methodology of nanoemulsion preparation using oily polymer for the delivery of poorly soluble drugs","volume":"10","author":"Wik","year":"2020","journal-title":"Drug Deliv. Transl. Res."},{"issue":"1","key":"10.1016\/j.exer.2025.110456_bib123","doi-asserted-by":"crossref","first-page":"6604","DOI":"10.1038\/s41598-018-24545-2","article-title":"Evaluation of subconjunctival liposomal steroids for the treatment of experimental uveitis","volume":"8","author":"Wong","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.exer.2025.110456_bib124","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.actbio.2017.05.024","article-title":"Calcium ion coordinated dexamethasone supramolecular hydrogel as therapeutic alternative for control of non-infectious uveitis","volume":"61","author":"Wu","year":"2017","journal-title":"Acta Biomater."},{"key":"10.1016\/j.exer.2025.110456_bib125","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.actbio.2018.04.019","article-title":"Glycosylation-enhanced biocompatibility of the supramolecular hydrogel of an anti-inflammatory drug for topical suppression of inflammation","volume":"73","author":"Xiong","year":"2018","journal-title":"Acta Biomater."},{"issue":"2","key":"10.1016\/j.exer.2025.110456_bib126","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1517\/17425247.3.2.261","article-title":"Drug delivery from ocular implants","volume":"3","author":"Yasukawa","year":"2006","journal-title":"Expet Opin. Drug Deliv."},{"issue":"7","key":"10.1016\/j.exer.2025.110456_bib127","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1167\/iovs.09-4373","article-title":"Treatment of experimental autoimmune uveoretinitis with intravitreal injection of tacrolimus (FK506) encapsulated in liposomes","volume":"51","author":"Zhang","year":"2010","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"12","key":"10.1016\/j.exer.2025.110456_bib128","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1136\/bjophthalmol-2016-310044","article-title":"Treatment of experimental autoimmune uveoretinitis with intravitreal injection of infliximab encapsulated in liposomes","volume":"101","author":"Zhang","year":"2017","journal-title":"Br. J. Ophthalmol."},{"issue":"7","key":"10.1016\/j.exer.2025.110456_bib129","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1166\/jbn.2021.3118","article-title":"A novel indomethacin-tripeptide hydrogel for inhibiting ocular inflammation","volume":"17","author":"Zhang","year":"2021","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.exer.2025.110456_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2021.129623","article-title":"Dexamethasone-peptide prodrug supramolecular hydrogel effectively alleviates experimental autoimmune uveitis (EAU)","volume":"421","author":"Zhang","year":"2021","journal-title":"Chem. Eng. J."},{"issue":"6","key":"10.1016\/j.exer.2025.110456_bib131","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1021\/bm5003009","article-title":"Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy","volume":"15","author":"Zhong","year":"2014","journal-title":"Biomacromolecules"},{"issue":"3","key":"10.1016\/j.exer.2025.110456_bib132","first-page":"390","article-title":"Nanoparticles in the ocular drug delivery","volume":"6","author":"Zhou","year":"2013","journal-title":"Int. J. Ophthalmol."},{"key":"10.1016\/j.exer.2025.110456_bib133","series-title":"Developing Solid Oral Dosage Forms","first-page":"297","article-title":"Oral absorption basics: pathways and physicochemical and biological factors affecting absorption","author":"Zhu","year":"2017"},{"issue":"17","key":"10.1016\/j.exer.2025.110456_bib134","doi-asserted-by":"crossref","first-page":"9184","DOI":"10.3390\/ijms25179184","article-title":"Applications of biological therapy for latent infections: benefits and risks","volume":"25","author":"Zong","year":"2024","journal-title":"Int. J. Mol. Sci."}],"container-title":["Experimental Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483525002271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483525002271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T04:24:03Z","timestamp":1778473443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014483525002271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":127,"alternative-id":["S0014483525002271"],"URL":"https:\/\/doi.org\/10.1016\/j.exer.2025.110456","relation":{},"ISSN":["0014-4835"],"issn-type":[{"value":"0014-4835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breaking barriers in ocular drug delivery for Uveitis: Advanced drug delivery systems, challenges and future prospects","name":"articletitle","label":"Article Title"},{"value":"Experimental Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exer.2025.110456","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110456"}}